You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:

Novo Nordisk statement

Author: Novo Nordisk, Published on: 23 November 2015

We support a mandatory reporting mechanism for European companies that manufacture or contract to manufacture products containing 3TG necessary to product functionality or manufacture.  The reporting mechanism should mirror the US Securities and Exchange Commission requirements to ensure a consistent international framework.

This is a response from the following companies: Novo Group Novo Nordisk (part of Novo Group)